subject: Generic Prescriptions In The U.s. Market Accounted For 75% Growth [print this page] IMSHealth company news release April 1, 2009 and non-retail channels U.S. retail sales of prescription drugs and insulin type Drugs Sell 5.1% growth in sales to 300.3 billion U.S. dollars. The 2008 U.S. prescription sales growth of just 1.8%.
IMSInsight MurrayAitken senior vice president, said: "drug demand in 2009 than before 2009 and in 2008 strong, but still historically low. Although there are 32 innovative drugs last year, introduced to the suffering Cancer , Thrombosis and atrial fibrillation in patients with various diseases brought about new drug options, but the pull of drug consumption growth is limited. First use of the treatment of epilepsy, migraine, and immune system diseases, low-cost Generic The role of the market growth moderate over the past few years. Prescription drugs in 2009 were more robust on demand, including new therapies and complementary therapies to use both to promote drug treatment market bounced back. "
Lead to the growth of the U.S. market in 2009 include:
macro-economic downturn under the strong demand for prescription drugs. Retail prescription drug sales grew 2.1% in volume of 3.9 billion prescriptions dispensed over the 2008 increase of 1.0%. Although chronic treatment of 17 major areas of new therapy for about 1% decline, additional therapy, therapy changes and complementary therapy increased nearly 2%.
Pharmacy Business continued pricing, based on clinical evidence and based on the value of competition.
2009 retail pharmacy inventory management actions initiated so that inventory levels in line with market demand.
greater use of the treatment of complex and chronic disease-specific drugs?? Such products sales accounted for 21% of the U.S. pharmaceutical market, up 7.5% over the previous year;
little effect on drug patents expire, and last year no significant drug safety problem.
IMS Company believes that the main treatment field in the following major trends:
antipsychotic drugs are still the most popular drug in the United States in 2009, prescription sales reached 14.6 billion U.S. dollars, and 2008 unchanged.
lipid transfer prescription drugs is still the largest U.S. treatment drugs, in 2009 amounted to 212 million prescriptions, an increase of 5%. Lipid transfer of drug sales last year, reduced by 10% on sales of 13.1 billion U.S. dollars, reflecting the shift to low-cost generic versions of the trend. Lipid transfer of drug sales in 2009, the third largest.
proton Pump Lipid transfer inhibitor drugs to replace drugs as the second highest sales in the treatment of type drugs. Proton pump inhibitors 13.6 billion in sales, down 2% from last year, the class of drug prescriptions increased 5%.
antidepressant drugs as 2009, the fourth annual sales, ranked fifth in 2008, according to prescription sales growth of 3% to 99 million.
include Advastin, MabThera and Herceptin anti-tumor monoclonal antibodies, including sales growth of 9% in the treatment of drugs in the sixth class.
IMS in the latest analysis report, including brand generic use of generic drugs, including continued growth in 2009, prescriptions in the United States accounted for 75%, while only 57% in 2004. Prescription of generic drugs in 2009 grew 5.9% over the same period of branded prescription drug prescriptions declined 7.6%. MurrayAitken that the 2009 changes in patients with multiple factors, including more options on generic drugs, patent medicines and generic drugs to pay their own differences and the proportion of more patients, insurers and employers to encourage the appropriate use of low-cost alternatives.
"The use of generic drugs continue to grow in 2009, prescriptions in the United States accounted for 75%, while only 57% in 2004."
Generic Prescriptions In The U.s. Market Accounted For 75% Growth
